MANAGEMENT OF YOUNG PATIENTS WITH MARFAN SYNDROME
Marfan syndrome is a hereditary, autosomal disease with a relatively high prevalence in the general population. Numerous manifestations of Marfan syndrome are expressed in a wide range of disorders involving cardiovascular, ocular and musculoskeletal systems. The article describes the principles of management of the syndrome in children and adolescents. Clinical manifestations of the disease are evaluated in young patients of different age groups. There are presented data on the main medicines used in the therapy of Marfan syndrome, such as beta-blockers, angiotensin receptor blockers, statins. Relevant literature was searched using the databases PubMed, MedLine, Scopus, Web of Science. The article will be interesting to a wide range of specialists: pediatricians, cardiologists, general practitioners and other specialties
About the authorsLuneva Ekaterina B.
Singh M.N., Lacro R.V. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. Canadian Journal of Cardiology. 2016; 32(1): 66-77.
Cheung Y.F., Chow P.C, So E.K., Circulating Transforming Growth Factor-β and Aortic Dilation in Patients with Repaired Congenital Heart Disease. Sci Rep. 2019 Jan 17;9(1):162.
Loeys B.L, Dietz H.C, Braverman A.C., The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-85.
Chiu H, Wu M, Wang J, Lu C. Losartan Added to ßblockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc. 2013; 88:271-6.
Bolar N., Van Laer L., Loeys, B. L. Marfan syndrome. Current Opinion in Pediatrics. 2012; 24(4), 498-504.
Tinkle B., Saal H., the committee on genetics. Health Supervision for Children With Marfan Syndrome Pediatrics Oct 2013; 132 (4) e1059-e1072.
Kodolitsch Y., De Backer J., Schüler H. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. The Application of Clinical Genetics. 2015:8 137-55.
Luneva E. B., Uspenskiy V. E., Mitrofanova L. B. Causes of thoracic aortic aneurysm formation. Rossiyskiy kardiologicheskiy zhurnal. 2013; 1 (99): 19-22 (in Russian).
Libbi P, Bonou R, Mann D. Braunwald heart disease. Cardiovascular Medicine Guideline. In 4 volumes Izdatel’stvo Rid Elsiver 2010, ch 56: 1464 (in Russian).
Groth K.A, Hove H, Kyhl K., Prevalence, incidence, and age at diagnosis in Marfan SyndromeGroth et al. Orphanet Journal of Rare Diseases. (2015) 10:153.
Faivre L, Masurel-Paulet A, Collod-Be´roud G, Callewaert B.L. Clinical and molecular study of 320 children with Marfan syndrome and related type 1 ﬁbrillinopathies in a series of 1009 probands with pathogenic FBN1mutations. Pediatrics. 2009; 123:391-8.
Rozendaal L, Blom N.A, Hilhorst-Hofstee Y. Dilatation of the great arteries in an infant with Marfan syndrome and ventricular septal defect. Case Rep Med. 2011; 1-5.
Liu L.-H., Lin S.-M., Lin D.-S. Losartan in combination with propranolol slows the aortic root dilatation in neonatal Marfan syndrome. Pediatrics and Neonatology. 2018; 59, 211-3.
Stheneur С., Tubach F, Jouneaux M., Study of phenotype evolution during childhood in Marfan syndrome to improve clinical recognition. Genetics in medicine. 2014; 3 Vol. 16: 246-50.
Dietz HC Marfan syndrome. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) Gene Reviews University of Washington, Seattle, WA, 2011; 1993-2011;
Wright MJ, Connolly HM, Otto CM, Yeon SB., Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders. Uptodate; 2012
Roman M.J, Devereux R.B, Kramer-Fox R, O’Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 1989;64 (8):507-12.
Gersony D.R, McClaughlin M, Zhezhen J, Gersony W. M. The effect of beta-blocker therapy on clinical outcome in patients with Marfan’s syndrome: a meta-analysis. Int J Cardiol. 2007; 303-8.
Mueller GC, Stierle L, Stark V. Retrospective analysis of the effect of angiotensin II receptor blocker versus b-blocker on aortic root growth in pediatric patients with Marfan syndrome. Heart. 2014; 100:214-8.
Takeda N., Yagi Н., Hara Н, Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes Int Heart J. 2016 May 25;57(3):271-7.
Roman M., Devereux R., Preiss L. Associations of Age and Sex With Marfan Phenotype The National Heart, Lung, and Blood Institute GenTAC (Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions). Registry Circ Cardiovasc Genet. 2017; 10:001647
Erbel R, Aboyans V, Boileau C, Bossone E, Di Bartolomeo R, Eggebrecht H et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Kardiol Pol. 2014;72(12):1169-252.
Hartog AW, Franken R, Zwinderman AH, Groenink M. Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin Pharmacother. 2012; 13(5):647-62.
Ladouceur M, Fermanian C, Lupoglazoff J. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007; 99:406-9
Tierney ESS, Feingold B, Printz BF. Betablocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr. 2007; 150:77-82
Gao L, Mao Q, Wen D, Zhang L The effect of betablocker therapy on progressive aortic dilatation in children and adolescents with Marfan’s syndrome: a meta-analysis. Acta Paediatr. 2011; 100:101-5.
Milleron O, Arnoult F, Ropers J. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015; 36(32):2160-6.
Lacro R.V., Dietz H.C., Sleeper L.A. Atenolol versus Losartan in Children and Young Adults with Marfan’s Syndrome; N Engl J Med. 2014;371:2061-71.
McLoughlin D, McGuinness J, Byrne J, et al. Pravastatin reduces Marfan aortic dilation. Circulation. 2011; 124: S168-73.
Sato T, Arakawa M, Tashima Y Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Ras-Induced ERK (Extracellular Signal-Regulated Kinase) Signaling Pathway. J Am Heart Assoc. 2018;7: e008543.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.